Date: 2016-03-02
Type of information: Nomination
Compound:
Company: Arsanis (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 2, 2016, Arsanis announced that Michael P. Gray has joined the company as chief financial officer and
chief business officer. Mr. Gray comes to Arsanis from Curi where he held a variety of leadership positions over the past 15 years, including chief financial officer, chief business officer and chief operating officer, and was instrumental in financial and business development transactions that raised over $350 million. At Arsanis, Mr. Gray will lead financial strategy, planning and operations as well as corporate and business development initiatives as the company continues to advance its deep clinical and preclinical pipeline of precision monoclonal antibodies for serious infectious diseases.
Prior to Curis, Mr. Gray served as Controller and de Facto Chief Financial Officer of Reprogenesis, and was as an audit professional for Ernst & Young, LLP. He earned an MBA in corporate finance and entrepreneurial management from the F.W. Olin Graduate School of Business at Babson College and holds a bachelor’s of science in accounting from Bryant College.
Financial terms:
Latest news:
